JNJ · Orin

—

Loading research…

Healthcare · Drug Manufacturers - General

Johnson & JohnsonJNJ

$228.39-5.81 · -2.48%

As of 6/18/2026, 8:00:02 PM · Market cap $549.78B · 52w $149.04–$251.71

buyCONF 0.70

Buy 21Hold 16Sell 3

Analyst target$251.55

Implied upside+10.1%

LineCandles

1M3M6M1YALL

scroll = zoom · drag = pan · double-click = reset · — 50d ┄ 200d MA · ▲ earningsCharts by TradingView

P/E (TTM)

27.4

Rev growth

+6%

Gross margin

72.8%

FCF margin

20.9%

Net income

$26.80B

Total debt

$47.93B

Thesis

deepseek/deepseek-v4

Johnson & Johnson is a buy. The company generated $94.2B in revenue and $19.7B in free cash flow in FY2025, reflecting steady growth and robust cash generation. Smart money sentiment turned sharply positive in Q1 2026, with 57 funds accumulating shares, signaling institutional conviction. Trading at a P/E of 27.2x, a modest premium to the peer median of 26.4x, JNJ offers a defensive growth profile underpinned by its Innovative Medicine and MedTech segments.

Patent Expirations

Loss of exclusivity on key pharmaceutical products could erode revenue and margins.

Regulatory/Pricing Pressure

Drug pricing reforms or changes in healthcare policy may compress profitability.

M&A Integration

Large acquisitions may fail to deliver expected synergies or strain the balance sheet.

Valuation Premium

JNJ trades at a 23% premium to peers on EV/EBITDA; multiple contraction could occur if growth disappoints.

✦ Ask Orin about JNJ

The 60-second read

one number per tab

Technicals

Buy

last cross: golden 2025-07-24

Valuation

27× P/E

100th pct of its own history

Smart money

0.3

institutional composite 0–10

Insiders

$-52.6M

net, last 24mo (130 buys / 132 sells)

Short interest

0.9%

of float sold short

What most people miss

rule-derived · no AI

Expensive vs its own history

P/E is 1.4σ above the stock's own multi-year range — the market is paying up vs precedent.

Golden cross on 2025-07-24

The 50d average crossed above the 200d — the classic long-trend confirmation.

Price and smart money disagree

The stock beats SPY (+52% vs +25%) while the institutional composite sits at 0.3 — retail momentum, not fund accumulation.

1Y vs S&P 500

stock +51.5% · SPY +25.0% · outperforming

Both lines indexed to 100 one year ago — the gap is your real edge (or drag) vs just buying the index.

Research only, not investment advice. Orin publishes general research output; your investment decisions are your own.